Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR study

Author(s): Krug, U; Ravandi, F; Ritchie, EK; Sayar, H; Lancet, JE; Craig, MD; Vey, N; Strickland, SA; Schiller, GJ; Jabbour, E; Erba, HP; Pigneux, A; Horst, H-A; Recher, C; Klimek, VM; Cortes, J; Roboz, GJ; Craig, AR; Fox, JA; Ward, R; Smith, JA; Acton, G; Mehta, C; Kantarjian, HM; Stuart, RK